Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00538902
First received: October 1, 2007
Last updated: April 7, 2011
Last verified: April 2011
Results First Received: November 23, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo
Biological: Adalimumab 80 mg
Biological: Adalimumab 40 mg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 12 weeks.
Adalimumab 40 mg Adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for 24 weeks.
Adalimumab 80 mg Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 12 weeks.

Participant Flow for 2 periods

Period 1:   DB Wk 0 Through 12 (Primary D/C Reasons)
    Placebo     Adalimumab 40 mg     Adalimumab 80 mg  
STARTED     60     121     121  
COMPLETED     59     119     116  
NOT COMPLETED     1     2     5  
Adverse Event                 1                 2                 3  
Withdrawal by Subject                 0                 0                 1  
Lost to Follow-up                 0                 0                 1  
Various                 0                 0                 0  

Period 2:   OL Wk 24 to End (Primary D/C Reasons)
    Placebo     Adalimumab 40 mg     Adalimumab 80 mg  
STARTED     59     119     116  
COMPLETED     23     55     52  
NOT COMPLETED     36     64     64  
Adverse Event                 2                 10                 11  
Withdrawal by Subject                 15                 19                 25  
Lost to Follow-up                 1                 10                 6  
Various                 18                 25                 22  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Adalimumab 40 mg Adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for 104 weeks.
Adalimumab 80 mg Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Total Total of all reporting groups

Baseline Measures
    Placebo     Adalimumab 40 mg     Adalimumab 80 mg     Total  
Number of Participants  
[units: participants]
  60     121     121     302  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     58     115     111     284  
>=65 years     2     6     10     18  
Gender  
[units: participants]
       
Female     49     104     101     254  
Male     11     17     20     48  
Region of Enrollment  
[units: participants]
       
China     60     121     121     302  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period   [ Time Frame: Week 12 ]

2.  Secondary:   Number of Participants Achieving American College of Rheumatology (ACR)50/70 at Week 12 of the Double-Blind Period   [ Time Frame: Week 12 ]

3.  Secondary:   Number of Participants Achieving American College of Rheumatology (ACR)20 Response Through Week 92 of Open-Label Period   [ Time Frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

4.  Secondary:   Number of Participants Achieving American College of Rheumatology (ACR)50 Response Through Week 92 of Open-Label Period   [ Time Frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

5.  Secondary:   Number of Participants Achieving American College of Rheumatology (ACR)70 Response Through Week 92 of Open-Label Period   [ Time Frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

6.  Secondary:   Mean Change in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12 of the Double-Blind Period   [ Time Frame: Baseline, Week 12 ]

7.  Secondary:   Mean Change in Tender Joint Count (TJC) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

8.  Secondary:   Mean Change in Swollen Joint Count (SJC) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

9.  Secondary:   Mean Change in Visual Analog Scale (VAS) Score at Week 12 of the Double-Blind Period   [ Time Frame: Baseline, Week 12 ]

10.  Secondary:   Mean Change in Physician's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

11.  Secondary:   Mean Change in Patient's Assessment of Pain (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

12.  Secondary:   Mean Change in Patient's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

13.  Secondary:   Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period   [ Time Frame: Baseline, Week 12 ]

14.  Secondary:   Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

15.  Secondary:   Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) and Mental Component Summary (MCS) at Week 12 of the Double-Blind Period   [ Time Frame: Baseline, Week 12 ]

16.  Secondary:   Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]

17.  Secondary:   Mean Change in the SF-36 Health Survey Index Mental Component Summary (MCS) Through Week 92 of the Open-Label Period   [ Time Frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: Abbott
phone: 800-633-9110


No publications provided


Responsible Party: Laura Redden MD, PhD, Project Director, Abbott
ClinicalTrials.gov Identifier: NCT00538902     History of Changes
Other Study ID Numbers: M04-705
Study First Received: October 1, 2007
Results First Received: November 23, 2009
Last Updated: April 7, 2011
Health Authority: China: Food and Drug Administration